Document is current
Any future updates will be listed below
-
Authors
Nshanian, Michael
Gruber, Joshua J.
Geller, Benjamin S.
Chleilat, Faye https://orcid.org/0000-0002-0804-1611
Lancaster, Samuel M.
White, Shannon M. https://orcid.org/0000-0002-1351-943X
Alexandrova, Ludmila https://orcid.org/0000-0002-1203-4166
Camarillo, Jeannie M.
Kelleher, Neil L.
Zhao, Yingming https://orcid.org/0000-0003-1928-2151
Snyder, Michael P. https://orcid.org/0000-0003-0784-7987
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (3UM1HG009442-04S1, 3UM1HG009442-04S1)
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (K08CA245024)
- License Information
-
More Information
Article History
Received: 6 February 2024
Accepted: 26 November 2024
First Online: 9 January 2025
Competing interests
: M.P.S. is a cofounder and scientific advisor of Crosshair Therapeutics, Exposomics, Filtricine, Fodsel, iollo, InVu Health, January AI, Marble Therapeutics, Mirvie, Next Thought AI, Orange Street Ventures, Personalis, Protos Biologics, Qbio, RTHM and SensOmics. M.P.S. is a scientific advisor of Abbratech, Applied Cognition, Enovone, Jupiter Therapeutics, M3 Helium, Mitrix, Neuvivo, Onza, Sigil Biosciences, TranscribeGlass, WndrHLTH and Yuvan Research. M.P.S. is a cofounder of NiMo Therapeutics. M.P.S. is an investor and scientific advisor of R42 and Swaza. M.P.S. is an investor in Repair Biotechnologies. Y.Z. is a consultant and an equity holder with PTM Bio, where anti-propionyl–lysine antibodies were purchased. All other authors declare no competing interests.
